With regular use, youll notice a visible improvement in your skin's texture and tone
Neurological manifestations of patients with COVID-19: potential routes of SARS-CoV-2 neuroinvasion from the periphery to the brain
Ingelheim, Germany - Boehringer Ingelheim today announces the start of a Phase II clinical trial evaluating its investigational triple GLP-1/GIP/NPY2 receptor agonist, BI 3034701, in patients with obesity and overweight.1 The trial represents a significant milestone for Boehringers cardiometabolic and obesity pipeline, which aims to address obesity as a central driver of interconnected cardiovascular, renal and metabolic conditions.5,6 Obesity is a complex, chronic disease that impacts more than 1 in 8 people worldwide in many different ways, and can have serious long-term consequences.7,8 Due to the heterogeneity of the disease, different mechanisms are needed to address different patient needs, disease stages, and risk profiles.8,9 BI 3034701 is a potential first-in-class triple agonist designed to activate the GLP1, GIP, and NPY2 receptors.1 By engaging these three complementary biological pathways, the molecule aims to address obesity through simultaneously targeting the regulation of body weight and metabolism.2,3,4 While the impact of GLP-1 and GIP on satiety, weight, and metabolic regulation is well established,2 NPY2R agonism provides a potentially differentiated mechanism that is still being investigated
Lancet 397:18301841 Shulman A, Peltonen M, Sjstrm CD et al (2018) Incidence of end-stage renal disease following bariatric surgery in the Swedish obese subjects study
The visits run through Google Meet embedded in the patient portal and last around 1015 minutes each
